IP Library Granted Patent US 9,693,966
Granted Patent B2
US 9,693,966 · App. 12/716,593 · Granted Jul 4, 2017

Gastric reflux resistant dosage forms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,693,966
App. No.
12/716,593
Granted
Jul 4, 2017
Kind
B2
Abstract

Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.

Claims (41)

1. An oral gastric resistant soft capsule shell comprising

(a) about 2% to about 5% pectin by weight of the capsule shell;

(b) about 25% to about 40% gelatin by weight of the capsule shell; and

(c) less than about 2% by weight of the capsule shell of a gelling agent comprising calcium salts, magnesium salts, or calcium gelatin.

2. The shell of claim 1 , wherein the gelling agent comprises less than about 1% by weight of the shell.

3. The shell of claim 1 , further comprising one or more plasticizers comprising glycerol, sorbitol, sorbitans, maltitol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate, or combinations thereof.

4. The shell of claim 3 , wherein the one or more plasticizers comprises from about 8% to about 30% by weight of the shell.

5. The shell of claim 1 , further comprising a fill material.

6. The shell of claim 5 , wherein the fill material comprises a liquid, semi-solid, or solid.

7. The shell of claim 5 , wherein the fill material comprises one or more therapeutic, prophylactic, or diagnostic agents; and optionally one or more pharmaceutically acceptable excipients.

8. The shell of claim 1 , wherein the pectin comprises high (methyl) ester pectin.

9. The shell of claim 1 , wherein the pectin comprises low (methyl) ester pectin.

10. The shell of claim 1 , wherein the pectin comprises amidated pectin.

11. The shell of claim 5 , wherein the fill material comprises fish oil.

12. An oral gastric resistant dosage form comprising a soft capsule shell comprising

(a) about 2% to about 5% pectin by weight of the capsule shell;

(b) about 25% to about 40% gelatin by weight of the capsule shell; and

(c) less than about 2% by weight of the capsule shell of a gelling agent comprising calcium salts, magnesium salts, or calcium gelatin;

(d) about 8% to about 30% by weight of the capsule shell of a plasticizer comprising glycerol, sorbitol, or a combination thereof; and

a fill comprising a pharmaceutically active agent or a nutritional, and optionally one or more pharmaceutically acceptable excipients.

13. An oral gastric resistant dosage form comprising a soft capsule shell encapsulating a fill, the shell comprising

(a) about 2% to about 5% pectin by weight of the capsule shell;

(b) about 25% to about 40% gelatin by weight of the capsule shell; and

(c) less than about 2% by weight of the capsule shell of a gelling agent comprising calcium salts, and

(d) about 8% to about 30% by weight of the capsule shell of a plasticizer comprising glycerol; and

a fill comprising fish oil.

14. The shell of claim 3 , wherein the plasticizer comprises glycerol.

15. The shell of claim 1 , further comprising glycerol in an amount of about 8% to about 30% by weight of the capsule shell.

16. The shell of claim 1 , further comprising water.

17. The shell of claim 1 , wherein pectin comprises about 3% by weight of the capsule shell.

18. The shell of claim 1 , wherein the gelling agent comprises a calcium salt.

19. The shell of claim 1 , wherein the gelling agent comprises about 0.01% by weight of the capsule shell.

20. The dosage form of claim 12 , wherein the plasticizer comprises glycerol.

21. The dosage form of claim 12 , wherein the shell further comprises water.

22. The dosage form of claim 12 , wherein pectin comprises about 3% by weight of the capsule shell.

23. The dosage form of claim 12 , wherein the gelling agent comprises a calcium salt.

24. The dosage form of claim 12 , wherein the gelling agent comprises about 0.01% by weight of the capsule shell.

25. The dosage form of claim 12 , wherein the fill comprises fish oil.

26. The dosage form of claim 13 , wherein the shell further comprises water.

27. The dosage form of claim 13 , wherein pectin comprises about 3% by weight of the capsule shell.

28. The dosage form of claim 13 , wherein the gelling agent comprises about 0.01% by weight of the capsule shell.

Assignments (11)
RELEASE (REEL 032403 / FRAME 0790) Recorded Sep 28, 2017
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BANNER PHARMACAPS INC.
Reel/Frame 044038/0028 →
NOTICE OF SUCCESSION OF AGENCY FOR PATENT SECURITY INTEREST PREVIOUSLY RECORDED AT REEL/FRAME (032403/0790) Recorded Jul 12, 2017
From: UBS AG, STAMFORD BRANCH, AS PRIOR AGENT
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS SUCCESSOR AGENT
Reel/Frame 043173/0005 →
NUNC PRO TUNC ASSIGNMENT Recorded Jun 29, 2017
From: BANNER LIFE SCIENCES LLC
To: PATHEON SOFTGELS INC
Reel/Frame 043032/0619 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED AT REEL: 034359 FRAME: 872. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 5, 2015
From: BANNER PHARMACAPS INC.
To: BANNER LIFE SCIENCES LLC
Reel/Frame 037055/0101 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2015
From: UBS AG, STAMFORD BRANCH
To: BANNER LIFE SCIENCES LLC; BANNER PHARMACAPS INC.
Reel/Frame 036224/0623 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2015
From: UBS AG, STAMFORD BRANCH
To: BANNER LIFE SCIENCES LLC
Reel/Frame 036239/0188 →
SECURITY INTEREST Recorded Mar 5, 2015
From: BANNER LIFE SCIENCES LLC
To: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT
Reel/Frame 035133/0328 →
CHANGE OF NAME Recorded Dec 3, 2014
From: BANNER PHARMACAPS INC.
To: BANNER LIFE SCIENCES LLC
Reel/Frame 034359/0872 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS Recorded Apr 23, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: BANNER PHARMACAPS INC.
Reel/Frame 032745/0454 →
SECURITY INTEREST Recorded Mar 11, 2014
From: BANNER PHARMACAPS INC.
To: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT
Reel/Frame 032403/0790 →
SECURITY AGREEMENT Recorded Dec 17, 2012
From: BANNER PHARMACAPS INC.
To: MORGAN STANLEY SENIOR FUNDING INC., AS COLLATERAL AGENT
Reel/Frame 029481/0962 →